Biomarin Pharmaceutical Inc. (BMRN)

$88.38

-0.44

(-0.5%)▲

Market is closed - opens 7 PM, 21 Sep 2023

Insights on Biomarin Pharmaceutical Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 505.34M → 595.27B (in $), with an average increase of 38.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -34.86M → 56.04B (in $), with an average increase of 134.2% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 91.9% return, outperforming this stock by 87.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 176.0% return, outperforming this stock by 161.1%

Performance

  • $88.01
    $89.66
    $88.38
    downward going graph

    0.42%

    Downside

    Day's Volatility :1.84%

    Upside

    1.42%

    downward going graph
  • $80.53
    $117.77
    $88.38
    downward going graph

    8.88%

    Downside

    52 Weeks Volatility :31.62%

    Upside

    24.96%

    downward going graph

Returns

PeriodBiomarin Pharmaceutical Inc.Sector (Health Care)Index (Russel 2000)
3 Months
-8.26%
0.0%
0.0%
6 Months
-4.02%
3.0%
-0.5%
1 Year
4.35%
7.2%
0.4%
3 Years
14.93%
27.5%
19.1%

Highlights

Market Capitalization
16.7B
Book Value
$25.42
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
0.52
PE Ratio
170.81
PEG Ratio
0.64
Wall Street Target Price
117.18
Profit Margin
4.47%
Operating Margin TTM
4.15%
Return On Assets TTM
0.91%
Return On Equity TTM
2.15%
Revenue TTM
2.2B
Revenue Per Share TTM
11.98
Quarterly Revenue Growth YOY
11.5%
Gross Profit TTM
1.6B
EBITDA
194.0M
Diluted Eps TTM
0.52
Quarterly Earnings Growth YOY
0.98
EPS Estimate Current Year
1.02
EPS Estimate Next Year
2.43
EPS Estimate Current Quarter
0.23
EPS Estimate Next Quarter
0.26

Analyst Recommendation

Buy
    67%Buy
    29%Hold
    3%Sell
Based on 31 Wall street analysts offering stock ratings for Biomarin Pharmaceutical Inc.(by analysts ranked 0 to 5 stars)
Based on 31 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
21
22
22
Hold
9
9
9
Sell
1
1
00

Analyst Forecast

What analysts predicted

Upside of 32.59%

Current $88.38
Target $117.18

Company Financials

FY17Y/Y Change
Revenue
1.3B
↑ 17.62%
Net Income
-117.0M
↓ 81.43%
Net Profit Margin
-8.91%
↑ 47.52%
FY18Y/Y Change
Revenue
1.5B
↑ 13.52%
Net Income
-77.2M
↓ 34.03%
Net Profit Margin
-5.18%
↑ 3.73%
FY19Y/Y Change
Revenue
1.7B
↑ 14.27%
Net Income
-23.8M
↓ 69.11%
Net Profit Margin
-1.4%
↑ 3.78%
FY20Y/Y Change
Revenue
1.9B
↑ 9.18%
Net Income
859.1M
↓ 3702.4%
Net Profit Margin
46.18%
↑ 47.58%
FY21Y/Y Change
Revenue
1.8B
↓ 0.76%
Net Income
-64.1M
↓ 107.46%
Net Profit Margin
-3.47%
↓ 49.65%
FY22Y/Y Change
Revenue
2.1B
↑ 13.53%
Net Income
141.6M
↓ 320.91%
Net Profit Margin
6.75%
↑ 10.22%
Q1 FY22Q/Q Change
Revenue
519.4M
↑ 15.46%
Net Income
120.8M
↓ 308.64%
Net Profit Margin
23.26%
↑ 36.13%
Q2 FY22Q/Q Change
Revenue
533.8M
↑ 2.78%
Net Income
27.7M
↓ 77.1%
Net Profit Margin
5.18%
↓ 18.08%
Q3 FY22Q/Q Change
Revenue
505.3M
↓ 5.33%
Net Income
-6.7M
↓ 124.05%
Net Profit Margin
-1.32%
↓ 6.5%
Q4 FY22Q/Q Change
Revenue
537.5M
↑ 6.37%
Net Income
-34.9M
↑ 424.16%
Net Profit Margin
-6.49%
↓ 5.17%
Q1 FY23Q/Q Change
Revenue
596.4M
↑ 10.95%
Net Income
50.9M
↓ 245.85%
Net Profit Margin
8.53%
↑ 15.02%
Q2 FY23Q/Q Change
Revenue
595.3B
↑ 99708.86%
Net Income
56.0B
↑ 110102.16%
Net Profit Margin
9.41%
↑ 0.88%
FY17Y/Y Change
Total Assets
4.6B
↑ 15.15%
Total Liabilities
1.8B
↑ 45.1%
FY18Y/Y Change
Total Assets
4.4B
↓ 4.45%
Total Liabilities
1.5B
↓ 20.02%
FY19Y/Y Change
Total Assets
4.7B
↑ 5.94%
Total Liabilities
1.6B
↑ 7.43%
FY20Y/Y Change
Total Assets
5.8B
↑ 24.69%
Total Liabilities
1.7B
↑ 11.12%
FY21Y/Y Change
Total Assets
6.0B
↑ 2.66%
Total Liabilities
1.7B
↓ 0.54%
FY22Y/Y Change
Total Assets
6.4B
↑ 6.19%
Total Liabilities
1.8B
↑ 2.27%
Q1 FY22Q/Q Change
Total Assets
6.1B
↑ 0.99%
Total Liabilities
1.7B
↓ 3.53%
Q2 FY22Q/Q Change
Total Assets
6.1B
↑ 1.37%
Total Liabilities
1.6B
↓ 1.82%
Q3 FY22Q/Q Change
Total Assets
6.3B
↑ 1.92%
Total Liabilities
1.7B
↑ 3.32%
Q4 FY22Q/Q Change
Total Assets
6.4B
↑ 1.77%
Total Liabilities
1.8B
↑ 4.51%
Q1 FY23Q/Q Change
Total Assets
6.4B
↑ 0.92%
Total Liabilities
1.8B
↑ 0.15%
FY17Y/Y Change
Operating Cash Flow
-8.8M
↓ 96.16%
Investing Cash Flow
-305.5M
↓ 36.89%
Financing Cash Flow
507.1M
↓ 30.25%
FY18Y/Y Change
Operating Cash Flow
20.2M
↓ 330.76%
Investing Cash Flow
264.4M
↓ 186.54%
Financing Cash Flow
-388.0M
↓ 176.51%
FY19Y/Y Change
Operating Cash Flow
48.3M
↑ 138.83%
Investing Cash Flow
-31.0M
↓ 111.74%
Financing Cash Flow
-74.7M
↓ 80.75%
FY20Y/Y Change
Operating Cash Flow
85.4M
↑ 76.88%
Investing Cash Flow
-53.6M
↑ 72.83%
Financing Cash Flow
181.1M
↓ 342.54%
FY21Y/Y Change
Operating Cash Flow
304.5M
↑ 256.75%
Investing Cash Flow
-366.3M
↑ 583.15%
Financing Cash Flow
-48.0K
↓ 100.03%
Q1 FY22Q/Q Change
Operating Cash Flow
-45.4M
↓ 506.36%
Investing Cash Flow
87.8M
↓ 258.39%
Financing Cash Flow
-25.3M
↓ 275.6%
Q2 FY22Q/Q Change
Operating Cash Flow
56.2M
↓ 223.76%
Investing Cash Flow
-29.7M
↓ 133.83%
Financing Cash Flow
-11.8M
↓ 53.4%
Q3 FY22Q/Q Change
Operating Cash Flow
158.3M
↑ 181.58%
Investing Cash Flow
-23.4M
↓ 21.2%
Financing Cash Flow
7.5M
↓ 164.02%
Q1 FY23Q/Q Change
Operating Cash Flow
-73.9M
↓ 1189.48%
Investing Cash Flow
-30.0M
-
Financing Cash Flow
-40.7M
↓ 474.85%

Technicals Summary

Sell

Neutral

Buy

Biomarin Pharmaceutical Inc. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc.
-1.66%
-4.02%
4.35%
14.93%
-9.22%
Moderna, Inc.
Moderna, Inc.
-3.91%
-29.82%
-15.12%
54.11%
473.87%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.9%
10.13%
22.22%
50.58%
114.4%
Novo Nordisk A/s
Novo Nordisk A/s
2.45%
29.29%
91.93%
176.03%
299.56%
Seagen, Inc.
Seagen, Inc.
7.77%
4.2%
47.16%
16.48%
167.89%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
2.14%
18.37%
27.77%
35.7%
98.94%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc.
170.81
170.81
0.64
1.02
0.02
0.01
0.0
25.42
Moderna, Inc.
Moderna, Inc.
35.66
35.66
0.0
-3.66
0.07
0.01
0.0
44.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
22.39
22.39
9.01
41.82
0.19
0.1
0.0
225.94
Novo Nordisk A/s
Novo Nordisk A/s
43.6
43.6
2.03
3.3
0.82
0.22
0.01
2.52
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-3.47
-0.26
-0.13
0.0
13.96
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
27.75
27.75
0.41
14.71
0.25
0.16
0.0
60.01
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biomarin Pharmaceutical Inc.
Biomarin Pharmaceutical Inc.
Buy
$16.7B
-9.22%
170.81
4.47%
Moderna, Inc.
Moderna, Inc.
Buy
$39.6B
473.87%
35.66
11.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$90.8B
114.4%
22.39
33.93%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$834.9B
299.56%
43.6
33.4%
Seagen, Inc.
Seagen, Inc.
Hold
$38.9B
167.89%
NA
-33.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$92.5B
98.94%
27.75
35.4%

Institutional Holdings

  • PRIMECAP Management Company

    9.77%

  • Vanguard Group Inc

    9.43%

  • Dodge & Cox

    7.59%

  • BlackRock Inc

    7.45%

  • Capital Research Global Investors

    3.59%

  • State Street Corporation

    3.16%

Company Information

biomarin is a global pharmaceutical company focused on developing first-in-class and best-in-class therapeutics that provide meaningful advances to patients who live with serious and life-threatening rare genetic diseases. we remain steadfast to our original mission—to bring new treatments to market that will make a big impact on small patient populations. these patient populations are mostly children, suffering from diseases so rare, that the entire patient population can number as few as 1,000 people worldwide. these conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options and are usually ignored. time is critical to patients with rare diseases, and we strive to quickly develop important therapies for them. the efficiency and speed of our research, development, manufacturing, and commercial efforts is at the heart of our ability to urgently deliver therapies. our track record of developing and commercializing new treatment

Organization
Biomarin Pharmaceutical Inc.
Employees
3082
CEO
Mr. Jean-Jacques Bienaime M.B.A., MBA
Industry
Health Technology

Discover More

FAQs